In vitro susceptibility of filamentous fungal isolates from a corneal ulcer clinical trial

American Journal of Ophthalmology

Volumn 157, Issue 2, 2014, Pages 318-326

  Lalitha, Prajna ^a   Sun, Catherine Q ^b   Prajna, N Venkatesh ^a   Karpagam, Rajarathinam ^a   Geetha, Manoharan ^a   O'Brien, Kieran S ^b   Cevallos, Vicky ^b   McLeod, Stephen D ^b,c   Acharya, Nisha R ^b,c   Lietman, Thomas M ^b,c  

^a ARAVIND EYE CARE SYSTEM   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATAMYCIN; VORICONAZOLE;

ADULT; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASPERGILLUS; ASPERGILLUS FUMIGATUS; COMPARATIVE STUDY; CONTROLLED STUDY; CORNEA ULCER; CURVULARIA; DOUBLE BLIND PROCEDURE; FEMALE; FUNGUS ISOLATION; FUSARIUM; HUMAN; IN VITRO STUDY; KERATOMYCOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTIFUNGAL AGENTS; CORNEAL ULCER; DOUBLE-BLIND METHOD; EYE INFECTIONS, FUNGAL; FEMALE; FUNGI; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOSES; NATAMYCIN; PYRIMIDINES; TRIAZOLES;

EID: 84892576868     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2013.10.004     Document Type: Article

References (43)

1. J.P. Whitcher, M. Srinivasan, and M.P. Upadhyay Corneal blindness: a global perspective Bull World Health Organ 79 3 2001 214 221
2. M. Srinivasan, C.A. Gonzales, and C. George et al. Epidemiology and aetiological diagnosis of corneal ulceration in Madurai, South India Br J Ophthalmol 81 11 1997 965 971
3. M. Srinivasan Fungal keratitis Curr Opin Ophthalmol 15 4 2004 321 327
4. D.M. O'Day Selection of appropriate antifungal therapy Cornea 6 4 1987 238 245
5. F.B. Marangon, D. Miller, J.A. Giaconi, and E.C. Alfonso In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens Am J Ophthalmol 137 5 2004 820 825
6. P. Lalitha, B.L. Shapiro, and M. Srinivasan et al. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis Arch Ophthalmol 125 6 2007 789 793
7. P. Lalitha, N.V. Prajna, and C.E. Oldenburg et al. Organism, minimum inhibitory concentration, and outcome in a fungal corneal ulcer clinical trial Cornea 31 6 2012 662 667
8. R.A. Oechsler, M.R. Feilmeier, D. Miller, W. Shi, A.L. Hofling-Lima, and E.C. Alfonso Fusarium keratitis: genotyping, in vitro susceptibility and clinical outcomes Cornea 32 5 2013 667 673
9. N.J. Iqbal, A. Boey, B.J. Park, and M.E. Brandt Determination of in vitro susceptibility of ocular Fusarium spp. isolates from keratitis cases and comparison of Clinical and Laboratory Standards Institute M38-A2 and E test methods Diagn Microbiol Infect Dis 62 3 2008 348 350
10. P. Manikandan, J. Varga, and S. Kocsube et al. Epidemiology of Aspergillus keratitis at a tertiary care eye hospital in South India and antifungal susceptibilities of the causative agents Mycoses 56 1 2013 26 33
11. B.L. Shapiro, P. Lalitha, and A.R. Loh et al. Susceptibility testing and clinical outcome in fungal keratitis Br J Ophthalmol 94 3 2010 384 385
12. L. Pradhan, S. Sharma, S. Nalamada, S.K. Sahu, S. Das, and P. Garg Natamycin in the treatment of keratomycosis: correlation of treatment outcome and in vitro susceptibility of fungal isolates Indian J Ophthalmol 59 6 2011 512 514
13. H.G. Ozdemir, Y. Oz, M. Ilkit, and N. Kiraz Antifungal susceptibility of ocular fungal pathogens recovered from around the world against itraconazole, voriconazole, amphotericin B, and caspofungin Med Mycol 50 2 2012 130 135
14. N.V. Prajna, T. Krishnan, and J. Mascarenhas et al. The Mycotic Ulcer Treatment Trial: a randomized trial comparing natamycin vs voriconazole JAMA Ophthalmol 131 4 2013 422 429
15. Clinical and Laboratory Standards Institute Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi. 2nd ed. Approved standard M38-A2 2008 CLSI Wayne, PA
16. J.A. Giaconi, F.B. Marangon, D. Miller, and E.C. Alfonso Voriconazole and fungal keratitis: a report of two treatment failures J Ocul Pharmacol Ther 22 6 2006 437 439
17. M. Homa, C.S. Shobana, and Y.R. Singh et al. Fusarium keratitis in South India: causative agents, their antifungal susceptibilities and a rapid identification method for the Fusarium solani species complex Mycoses 56 5 2013 501 511
18. N. Kondori, E. Svensson, and I. Mattsby-Baltzer In vitro susceptibility of filamentous fungi to itraconazole, voriconazole and posaconazole by Clinical and Laboratory Standards Institute reference method and E-test Mycoses 54 5 2011 E318 322
19. P. Lalitha, R. Vijaykumar, N.V. Prajna, and A.W. Fothergill In vitro natamycin susceptibility of ocular isolates of Fusarium and Aspergillus species: comparison of commercially formulated natamycin eye drops to pharmaceutical-grade powder J Clin Microbiol 46 10 2008 3477 3478
20. L. Li, Z. Wang, R. Li, S. Luo, and X. Sun In vitro evaluation of combination antifungal activity against Fusarium species isolated from ocular tissues of keratomycosis patients Am J Ophthalmol 146 5 2008 724 728
21. L. Wang, S. Sun, Y. Jing, L. Han, H. Zhang, and J. Yue Spectrum of fungal keratitis in central China Clin Experiment Ophthalmol 37 8 2009 763 771
22. A. Debourgogne, S. de Hoog, A. Lozniewski, and M. Machouart Amphotericin B and voriconazole susceptibility profiles for the Fusarium solani species complex: comparison between the E-test and CLSI M38-A2 microdilution methodology Eur J Clin Microbiol Infect Dis 31 4 2012 615 618
23. S.L. Edelstein, L. Akduman, B.H. Durham, A.W. Fothergill, and H.Y. Hsu Resistant Fusarium keratitis progressing to endophthalmitis Eye Contact Lens 38 5 2012 331 335
24. W.E. Sponsel, J.R. Graybill, H.L. Nevarez, and D. Dang Ocular and systemic posaconazole(SCH-56592) treatment of invasive Fusarium solani keratitis and endophthalmitis Br J Ophthalmol 86 7 2002 829 830
25. H. Taylan Sekeroglu, E. Erdem, and M. Yagmur et al. Successful medical management of recalcitrant Fusarium solani keratitis: molecular identification and susceptibility patterns Mycopathologia 174 3 2012 233 237
26. E.Y. Tu, D.L. McCartney, R.F. Beatty, K.L. Springer, J. Levy, and D. Edward Successful treatment of resistant ocular fusariosis with posaconazole (SCH-56592) Am J Ophthalmol 143 2 2007 222 227
27. L. Xie, H. Zhai, J. Zhao, S. Sun, W. Shi, and X. Dong Antifungal susceptibility for common pathogens of fungal keratitis in Shandong Province, China Am J Ophthalmol 146 2 2008 260 265
28. N. Nayak, G. Satpathy, S. Prasad, J.S. Titiyal, R.M. Pandey, and R.B. Vajpayee Molecular characterization of drug-resistant and drug-sensitive Aspergillus isolates causing infectious keratitis Indian J Ophthalmol 59 5 2011 373 377
29. V.N. Prajna, P.S. Lalitha, and J. Mascarenhas et al. Natamycin and voriconazole in Fusarium and Aspergillus keratitis: subgroup analysis of a randomised controlled trial Br J Ophthalmol 96 11 2012 1440 1441
30. B.R. Jones Principles in the management of oculomycosis. XXXI Edward Jackson memorial lecture Am J Ophthalmol 79 5 1975 719 751
31. N.V. Prajna, J. Mascarenhas, and T. Krishnan et al. Comparison of natamycin and voriconazole for the treatment of fungal keratitis Arch Ophthalmol 128 6 2010 672 678
32. P. Lalitha, N.V. Prajna, A. Kabra, K. Mahadevan, and M. Srinivasan Risk factors for treatment outcome in fungal keratitis Ophthalmology 113 4 2006 526 530
33. M.R. Rahman, G.J. Johnson, R. Husain, S.A. Howlader, and D.C. Minassian Randomised trial of 0.2% chlorhexidine gluconate and 2.5% natamycin for fungal keratitis in Bangladesh Br J Ophthalmol 82 8 1998 919 925
34. E.M. Johnson, A. Szekely, and D.W. Warnock In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi J Antimicrob Chemother 42 6 1998 741 745
35. A. Espinel-Ingroff, E. Canton, and J. Peman Updates in antifungal susceptibility testing of filamentous fungi Curr Fungal Infect Rep 3 3 2009 133 141
36. European Committee on Antimicrobial Susceptibility Testing. Voriconazole: rationale for the clinical breakpoints, version 1.0, 2012. Available at http://www.eucast.org. Accessed May 4, 2013.
37. W.W. Hope, M. Cuenca-Estrella, C. Lass-Florl, and M.C. Arendrup EUCAST Technical note on voriconazole and Aspergillus spp Clin Microbiol Infect 19 6 2013 E278 280
38. A. Espinel-Ingroff, D.J. Diekema, and A. Fothergill et al. Wild-type MIC distributions and epidemiological cutoff values for the triazoles and six Aspergillus spp. for the CLSI broth microdilution method (M38-A2 document) J Clin Microbiol 48 9 2010 3251 3257
39. M.A. Pfaller, D.J. Diekema, and M.A. Ghannoum et al. Wild-type MIC distribution and epidemiological cutoff values for Aspergillus fumigatus and three triazoles as determined by the Clinical and Laboratory Standards Institute broth microdilution methods J Clin Microbiol 47 10 2009 3142 3146
40. J.L. Rodriguez-Tudela, L. Alcazar-Fuoli, E. Mellado, A. Alastruey-Izquierdo, A. Monzon, and M. Cuenca-Estrella Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus Antimicrob Agents Chemother 52 7 2008 2468 2472
41. M. Pfaller, L. Boyken, and R. Hollis et al. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles J Clin Microbiol 49 2 2011 586 590
42. M.A. Pfaller, S.A. Messer, and L. Boyken et al. In vitro survey of triazole cross-resistance among more than 700 clinical isolates of Aspergillus species J Clin Microbiol 46 8 2008 2568 2572
43. J.H. Rex, and M.A. Pfaller Has antifungal susceptibility testing come of age? Clin Infect Dis 35 8 2002 982 989